Log out
My profile and settings
My bookmarks
Comment history
Please complete your account verification. Resend verification email.
today
This verification token has expired.
today
Your email address has been verified. Update my profile.
today
Your account has been deactivated. Sign in to re-activate your account.
today
View all newsletters in the newsletter archive
today
You are now unsubscribed from receiving emails.
today
Sorry, we were unable to unsubscribe you at this time.
today
0
0
Back to profile
Comment Items
You have not left any comments yet.
title
you replied to a comment:
name
description
Saved Posts
You haven’t bookmarked any posts yet.

Limbitless is working to change the way the world thinks about artificial limbs.

learn more
Become a Gates Notes Insider
Sign up
Log out
Personal Information
Title
Mr
Mrs
Ms
Miss
Mx
Dr
Cancel
Save
This email is already registered
Cancel
Save
Please verify email address. Click verification link sent to this email address or resend verification email.
Cancel
Save
Email and Notification Settings
Send me updates from Bill Gates
You must provide an email
On
Off
Send me Gates Notes survey emails
On
Off
Send me the weekly Top of Mind newsletter
On
Off
Email me comment notifications
On
Off
On-screen comment notifications
On
Off
Interests
Select interests to personalize your profile and experience on Gates Notes.
Saving Lives
Energy Innovation
Improving Education
Alzheimer's
Philanthropy
Book Reviews
About Bill Gates
Account Deactivation
Click the link below to begin the account deactivation process.
If you would like to permanently delete your Gates Notes account and remove it’s content, please send us a request here.

Incredible innovation

A promising new vaccine candidate to protect children from their #1 killer

More than 670,000 children die from pneumonia every year. A new vaccine could save many lives.

|
0

The leading cause of death among children under age 5 often begins with little more than a cough.

Followed by chills, fever, and nausea.

And then as the child’s lungs get flooded with fluid, each breath becomes a desperate gasp for air.

What I’m describing is known as pneumonia, an acute respiratory condition that kills over 670,000 children every year.

And here’s a sentence I find difficult to write: Nearly all those deaths could have been prevented.

Access to vaccines, diagnostic tools, and treatments can protect children from deadly pneumonia. But these solutions are often not available or accessible in many low- and middle-income countries, where children are at greatest risk.

Even as child deaths have declined by nearly 50 percent over the past two decades, deaths from pneumonia have remained stubbornly high.

That’s why our foundation is focused on improving access to and development of vaccines that can prevent it.

One of the most exciting areas of progress is the development of a powerful new vaccine designed to protect children against pneumococcal bacteria, which is the leading cause of deadly pneumonia. Of the 670,000 children who die from pneumonia ever year, pneumococcal pneumonia is responsible for killing 400,000 of them.

What makes this new vaccine unique is that it is designed to protect against 25 different types of pneumococcal bacteria, more than any other available vaccine. Existing pneumococcal vaccines protect against about half as many types of pneumococcal pneumonia. To address the remaining deaths from pneumococcal pneumonia, vaccines that offer broader protection like this new vaccine will be needed.

The vaccine, called IVT-PCV25, is being developed by Inventprise, a small biotechnology company based outside Seattle. I recently took a tour of their new vaccine manufacturing plant and got an update on their progress.

It was amazing to see the innovations underway at Inventprise. Making a vaccine that is effectively 25 vaccines in one is an extremely complex challenge. Past efforts to add more strains of pneumococcal bacteria to vaccines using conventional technologies have resulted in vaccines that didn’t produce a strong enough immune response. Inventprise intends to overcome this obstacle with its proprietary vaccine technology that is designed to guard against many types of pneumococcal bacteria without any decline in protection.

Inventprise’s new factory, supported by a grant from our foundation, is a highly automated facility that marks an important step forward in Inventprise’s development of the vaccine. Clinical trials of the vaccine are expected to begin later this year.